Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in severe eosinophilic asthma (China, Phase 3)
CTR20180827Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of mepolizumab in eosinophilic asthma (EA), sponsored by GSK. Started Aug 2018; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on CTR20180827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180827.